Why Erasca, Inc.’s (ERAS) Stock Is Up 5.80%
As of Friday, August 21, Erasca, Inc.’s ERAS share price has surged by 5.80%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company’s product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds; and Asana BioSciences, LLC to develop and commercialize ERAS-007 and certain other related compounds. The company has a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. for the evaluation of ERAS-0015. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
Commentary & Analysis
Why Erasca, Inc.’s (ERAS) Stock Is Down 5.46%
As of Wednesday, July 29, Erasca, Inc.’s ERAS share price has dipped by 5.46%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Erasca, Inc.’s (ERAS) Stock Is Down 5.93%
As of Thursday, July 16, Erasca, Inc.’s ERAS share price has dipped by 5.93%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Erasca, Inc.’s (ERAS) Stock Is Up 5.64%
As of Wednesday, July 15, Erasca, Inc.’s ERAS share price has surged by 5.64%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Erasca, Inc.’s (ERAS) Stock Is Up 7.23%
As of Tuesday, July 14, Erasca, Inc.’s ERAS share price has surged by 7.23%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | ERAS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $6,166.3 | $292.6 | 70% |
|
| Shares Out (Mil) | 311.3 | 54.4 | 83% |
|
| Institutional Ownership | 86.9% | 93.2% | 54% |
|
| Float (Mil) | 242.9 | 40.2 | 77% |
|
| Beta | 0.65 | 0.94 | 38% |
|
| Avg Daily Volume (000s) | 2,861 | 544 | 87% |
|
| Price Change (52-week) |
1,108% | 59.7% | 100% |
|
| Growth | ERAS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (4.1%) | (10.1%) | 35% |
|
| EPS (5yr) | 38.1% | 16.0% | 88 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (59.0%) | (15.6%) | 4% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 9 | 9 | 9 | |
| Current EPS | ($0.127) | ($0.969) | ($0.597) | |
| Month Ago EPS | ($0.120) | ($0.953) | ($0.553) | |
| # Rev Up | 2 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.124) | ($0.966) | ($0.572) | |
| Year/Year Chg | (10.6%) | 120.7% | 71.3% | |
| Financials | ERAS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($287) | ($43) | 5% |
|
| EPS (TTM) | ($0.971) | ($1.400) | 21% |
|
| Operating Cash Flow (TTM) (Mil) | ($98) | ($31) | 6% |
|
| Net Cash Flow (TTM) (Mil) | ($24) | $2 | 25% |
|
| Long-Term Debt (Q1) (Mil) | $39 | $4 | 37% |
|
| Enterprise Value (Q1) (Mil) | $6,159 | $164 | 66% |
|
| Valuation | ERAS | Industry Median |
Percentile (All Stocks) |
|
| P/B | 15.20 | 2.83 | 93% |
|
| P/E | na | 19.6 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | ERAS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 64.2% | na |
|
| Net Margin | na | (75.9%) | na |
|
| ROA | (65.2%) | (47.5%) | 9% |
|
| ROE | (78.2%) | (55.0%) | 11% |
|
| Liabilities to Assets | 16.8% | 29.6% | 11% |
|
| F-Score | 1 | 3 | 1% |
|
Erasca, Inc. did not pass any screens on 8/21/2026.
